Evidence map›Paper›PMID 37932241›Full record

ArticleHuman vaccines & immunotherapeutics2023

Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).

Ozan S Kumru, Sakshi Bajoria, Kawaljit Kaur, John M Hickey, Greta Van Slyke, Jennifer Doering, Katherine Berman, Charles Richardson, Hans Lien, Harry Kleanthous and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Ozan S KumruDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA.
Sakshi BajoriaDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA.
Kawaljit KaurDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA.
John M HickeyDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA.
Greta Van SlykeDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Jennifer DoeringDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Katherine BermanDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Charles RichardsonTechnical Operations, Icosavax, Seattle, WA, USA.
Hans LienQuality, Icosavax, Seattle, WA, USA.
Harry KleanthousDiscovery & Translational Sciences, Global Health, Bill and Melinda Gates Foundation, Seattle, WA, USA.
Nicholas J MantisDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Sangeeta B JoshiDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA.
David B VolkinDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA.
University of Kansas · USNew York State Department of Health · USWadsworth Center · USBill & Melinda Gates Foundation · USTechnical Solutions (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Second-generation COVID-19 vaccines with improved immunogenicity (e.g., breadth, duration) and availability (e.g., lower costs, refrigerator stable) are needed to enhance global coverage. In this work, we formulated a clinical-stage SARS-CoV-2 receptor-binding domain (RBD) virus-like particle (VLP) vaccine candidate (IVX-411) with widely available adjuvants. Specifically, we assessed the

Indexed as

COVID-19Vaccines, Virus-Like ParticleAdjuvants, ImmunologicAlum CompoundsAluminumAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesEmulsionsHumansMiceSARS-CoV-2Spike Glycoprotein, CoronavirusVaccines, SyntheticAdjuvants, ImmunologicAlum CompoundsAluminumaluminum sulfateAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesEmulsionsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, SyntheticVaccines, Virus-Like Particleadjuvantaluminum-saltantigenCpGemulsionformulationSARS-CoV-2stabilityVaccineVLP (virus-like particle)

Identifiers

PMID37932241
PMCPMC10760504
OpenAlexW4388442223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.